Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: A systematic review and meta-analysis
Currently, limited information is available to clinicians regarding the long-term efficacy of omalizumab treatment for allergic asthma. In this report, we aimed to (i) systematically review the evidence regarding the long-term efficacy of omalizumab in patients with persistent uncontrolled allergic...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Nature Publishing Group
2015
|
| Online Access: | http://hdl.handle.net/20.500.11937/55515 |
| _version_ | 1848759641509462016 |
|---|---|
| author | Lai, T. Wang, Shaobin Xu, Z. Zhang, C. Zhao, Y. Hu, Y. Cao, C. Ying, S. Chen, Z. Li, W. Wu, B. Shen, H. |
| author_facet | Lai, T. Wang, Shaobin Xu, Z. Zhang, C. Zhao, Y. Hu, Y. Cao, C. Ying, S. Chen, Z. Li, W. Wu, B. Shen, H. |
| author_sort | Lai, T. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Currently, limited information is available to clinicians regarding the long-term efficacy of omalizumab treatment for allergic asthma. In this report, we aimed to (i) systematically review the evidence regarding the long-term efficacy of omalizumab in patients with persistent uncontrolled allergic asthma, and to (ii) discuss the cost-effectiveness evidence published for omalizumab in this patient population. A comprehensive search for randomized controlled trials (RCTs 52 weeks) was performed, and six studies met our final inclusion criteria (n = 2,749). Omalizumab was associated with significant improvements in quality of life and the Global Evaluation of Treatment Effectiveness. Omalizumab also allowed patients to completely withdraw from inhaled corticosteroid therapy and did not increase the overall incidence of adverse events. However, there was insufficient evidence that omalizumab reduced the incidence of exacerbations, and the cost-effectiveness of omalizumab varied across studies. Our data indicated that omalizumab use for at least 52 weeks in patients with persistent uncontrolled allergic asthma was accompanied by an acceptable safety profile, but it lacked effect on the asthma exacerbations. Use of omalizumab was associated with a higher cost than conventional therapy, but these increases may be cost-effective if the medication is used in patients with severe allergic asthma. |
| first_indexed | 2025-11-14T10:03:07Z |
| format | Journal Article |
| id | curtin-20.500.11937-55515 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T10:03:07Z |
| publishDate | 2015 |
| publisher | Nature Publishing Group |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-555152017-09-13T16:11:25Z Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: A systematic review and meta-analysis Lai, T. Wang, Shaobin Xu, Z. Zhang, C. Zhao, Y. Hu, Y. Cao, C. Ying, S. Chen, Z. Li, W. Wu, B. Shen, H. Currently, limited information is available to clinicians regarding the long-term efficacy of omalizumab treatment for allergic asthma. In this report, we aimed to (i) systematically review the evidence regarding the long-term efficacy of omalizumab in patients with persistent uncontrolled allergic asthma, and to (ii) discuss the cost-effectiveness evidence published for omalizumab in this patient population. A comprehensive search for randomized controlled trials (RCTs 52 weeks) was performed, and six studies met our final inclusion criteria (n = 2,749). Omalizumab was associated with significant improvements in quality of life and the Global Evaluation of Treatment Effectiveness. Omalizumab also allowed patients to completely withdraw from inhaled corticosteroid therapy and did not increase the overall incidence of adverse events. However, there was insufficient evidence that omalizumab reduced the incidence of exacerbations, and the cost-effectiveness of omalizumab varied across studies. Our data indicated that omalizumab use for at least 52 weeks in patients with persistent uncontrolled allergic asthma was accompanied by an acceptable safety profile, but it lacked effect on the asthma exacerbations. Use of omalizumab was associated with a higher cost than conventional therapy, but these increases may be cost-effective if the medication is used in patients with severe allergic asthma. 2015 Journal Article http://hdl.handle.net/20.500.11937/55515 10.1038/srep08191 Nature Publishing Group unknown |
| spellingShingle | Lai, T. Wang, Shaobin Xu, Z. Zhang, C. Zhao, Y. Hu, Y. Cao, C. Ying, S. Chen, Z. Li, W. Wu, B. Shen, H. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: A systematic review and meta-analysis |
| title | Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: A systematic review and meta-analysis |
| title_full | Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: A systematic review and meta-analysis |
| title_fullStr | Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: A systematic review and meta-analysis |
| title_full_unstemmed | Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: A systematic review and meta-analysis |
| title_short | Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: A systematic review and meta-analysis |
| title_sort | long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis |
| url | http://hdl.handle.net/20.500.11937/55515 |